## Silvia Piantoni

## List of Publications by Citations

Source: https://exaly.com/author-pdf/7618447/silvia-piantoni-publications-by-citations.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44 824 15 28 g-index

56 1,118 4.5 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
44	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 584241	8.4	86
43	Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1286-1289	2.4	82
42	COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e549-e556	14.2	75
41	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 115-123	4.7	74
40	Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. <i>Blood Reviews</i> , <b>2021</b> , 46, 100745	11.1	60
39	Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 666-72	4.1	51
38	A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 499-506	2.6	47
37	Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D. <i>Lupus</i> , <b>2015</b> , 24, 49	0- <del>3</del> .6	42
36	Vitamin D and antiphospholipid syndrome. <i>Lupus</i> , <b>2012</b> , 21, 736-40	2.6	41
35	Clinical significance of IgA anti-cardiolipin and IgA anti-Iglycoprotein I antibodies. <i>Current Rheumatology Reports</i> , <b>2013</b> , 15, 343	4.9	39
34	Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. <i>Reumatismo</i> , <b>2012</b> , 64, 307-13	1.1	22
33	Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	20
32	Relationship Between Different Subpopulations of Circulating CD4+ T-lymphocytes and Microvascular Structural Alterations in Humans. <i>American Journal of Hypertension</i> , <b>2017</b> , 30, 51-60	2.3	18
31	Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. <i>Rheumatology International</i> , <b>2015</b> , 35, 1571-3	3.6	17
30	Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes. <i>Lupus</i> , <b>2018</b> , 27, 143-149	2.6	16
29	Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 433	5.6	15
28	Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease. <i>Rheumatology</i> , <b>2020</b> , 59, 1769-1770	3.9	14

## (2021-2018)

27	Decreased circulating T regulatory lymphocytes in obese patients undergoing bariatric surgery. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197178	3.7	12
26	Relationship between different subpopulations of circulating CD4+ T lymphocytes and microvascular or systemic oxidative stress in humans. <i>Blood Pressure</i> , <b>2017</b> , 26, 237-245	1.7	10
25	The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 2489-2490	3.9	10
24	Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors. <i>Lupus</i> , <b>2019</b> , 28, 210-216	2.6	10
23	Winter lupus flares are associated with low vitamin D levels in a retrospective longitudinal study of Italian adult patients. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 153-8	2.2	9
22	Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome <b>2020</b> ,		8
21	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. <i>Rheumatology</i> , <b>2017</b> , 56, 1874-1883	3.9	7
20	Response to: Correspondence on Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndromeWby Kawada. <i>Annals of the Rheumatic Diseases</i> , 2021,	2.4	7
19	Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 1065-9	3.9	4
18	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 572876	8.4	4
17	Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: Colchicine treatment in community healthcare setting to prevent severe COVID-19Uby Della-Torre. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	4
16	Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1218-1227	4.7	4
15	Circulating follicular helper T cells (CD4+CXCR5+ICOS+) decrease in patients with rheumatoid arthritis treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 685	2.2	3
14	CD8+ T cell profiles in patients with rheumatoid arthritis-the effects of costimulation blockade: comment on the article by Carvalheiro et al. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2273-4	9.5	2
13	Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences?. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 73, 76-82	3.9	2
12	Is cholecalciferol a potential disease-modifying anti-rheumatic drug for the management of rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 343-349	2.2	2
11	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 91-97	2.2	2
10	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 91-97	2.2	1

9	Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 849086	4.9	1	
8	Belimumab for systemic lupus erythematosus - Focus on lupus nephritis <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 2072143	4.4	1	
7	The Influence of Treatment of Inflammatory Arthritis During Pregnancy on the Long-Term Children <b>u</b> Outcome. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 626258	5.6	O	
6	Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of	5.6	О	
5	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis <i>Clinical Reviews in Allergy and Immunology</i> , <b>2022</b> , 1	12.3	O	
4	Topoisomerase I (SCL 70) Autoantibodies <b>2014</b> , 239-245			
3	Improvement of lupus-associated fatigue with modafinil: Report of two cases. <i>Lupus</i> , <b>2021</b> , 30, 1013-101 <u>6</u> 6			
2	Reports of three long-term lung disease following SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 2585-2587	19.7		

Reply to: Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis by Castellanos-Moreira et al. *Clinical and Experimental Rheumatology*, **2021**, 39, 114<sup>2.2</sup>